Nav: Home

New indicators to aid Crohn's disease diagnosis and treatment

March 09, 2017

The diagnosis, understanding and management of Crohn's disease may have just received a helping hand from a joint ASU Biodesign Institute and Mayo Clinic study aimed at developing a better blood test for the disease.

The study, led by Biodesign scientists Josh LaBaer and Ji Qiu, along with gastroenterologists Shabana Pasha and Jonathan Leighton from Mayo Clinic Arizona, successfully identified several molecules, called biomarkers, that were unique indicators found only in patients with Crohn's disease.

"If we are going to truly alter the natural history of Crohn's disease and help people, we needed to develop a new test for early, accurate diagnosis, as well as administrating appropriate therapy," said Josh LaBaer, the Biodesign Institute's interim executive director.

"We are particularly excited about the links between the immune response against self proteins and Crohn's disease, as this may give physicians a new avenue to explore both the potential cause and treatments," said LaBaer, who leads a team of 100-plus interdisciplinary scientists as director of the Virginia G. Piper Center for Personalized Diagnostics. Their broad vision focuses on the discovery and validation of biomarkers to provide early warning for those at risk of major illnesses, including cancer, autism and diabetes to improve patient outcomes.

The medical cause of Crohn's disease remains a mystery with no simple medical explanation or cure. But in the course of the disease, the body's own immune system is somehow triggered to attack the gut.

Knowing this, LaBaer and Qiu advanced a new approach, immunoproteomics, to broadly sift through the entire repertoire of immune system proteins in the blood and identify early bell weathers of Crohn's disease, the most common inflammatory bowel disease.

Crohn's currently afflicts about 3 out of 1,000 people in the U.S., and for some unknown reason, the incidence is also on the rise. Crohn's is often associated with chronic, debilitating stomach pain, diarrhea, and other symptoms that may come and go. One in five people will have to be hospitalized each year, and surgery may eventually be required for the most severely afflicted. Inflammation is often a sign that the immune system has been triggered.

Crohn's diagnosis can be very difficult, and involves either expensive medical imaging from MRIs, invasive biopsies, or cataloging the symptoms. Physicians' primary course of action is to help relieve patient's suffering from chronic gut pain and symptoms through anti-inflammatory drugs.

"There has been increasing evidence that suggests the Crohn's disease immune response may be a result of altered microbes in the gut or exposure to harmful toxins that will result in antibodies against microbial and human proteins being made that are very specific manifestation of the disease," said Ji Qiu. "Many blood-based biomarkers have been discovered, but currently commercially available blood tests have not been widely adapted into clinical practice because they fail to accurately diagnose Crohn's disease."

In the study, which relied on the Biobanks at Mayo Clinic Rochester and Mayo Clinic Arizona, they looked at the serum from 48 patients with Crohn's disease and compared them with the same number of age- and gender-matched healthy controls.

They identified several candidate biomarkers of the immune system, called autoantibodies, based on having a sensitivity of higher than 15 percent in the patients, then validated each of these in an independent set of patients and controls. Next, they took the best of these samples to create a biomarker panel to make their test as accurate as possible.

"Biomarker studies can be plagued with issues of sensitivity and specificity," said Qiu. "If we ultimately want to use these are routine tests in the clinic, we have to ensure that that they have the required classification performance in distinguishing patients from healthy controls and other gut disorders."

To do so, they started by probing patient and healthy control sera against thousands of proteins contained on a microscope slide in neat, tiny rows called arrays (in this case, 1906 unique proteins culled from LaBaer's human gene collection bank, called DNASU). Their invention, called nucleic acid programmable protein arrays (NAPPA), avoids making these arrays by timely and costly protein purification, but rather, by making fresh protein at the time of the test from a more stable DNA copy on the slide.

The strongest biomarker indicators were for bacterial flagellin antibodies, which showed the strongest reactivity and highest prevalence on the arrays, achieving a sensitivity of 46 percent at 95 percent specificity. A novel biomarker was the antibody against SNRPB, which plays a general role in making proteins. Interestingly, it has also been reported in Lupus patients, known as the "Smith antigen."

What does the detection of these autoantibodies mean in our understanding of Crohn's disease?

"One possibility is that these antibodies reflect dysregulated immune response in the gut," said LaBaer. "Another is that they could play a pathogenic role. But so far, we simply don't have enough such antibodies discovered to understand their functional role."

LaBaer points out that the 2,000 human proteins used in the study are but a small fraction of human and microbial proteins in the more than 30,000 unique proteins contained in their DNASU collection.

They are buoyed by the initial success of their study, and will conduct future expanded studies on autoantibodies and anti-microbial antibodies against Crohn's disease related microorganisms from microbiome studies.

"Ultimately, we know that no single biomarker is going to be predictive and meet clinical needs," said LaBaer. "Only a panel of biomarkers, made of individually validated biomarkers, will achieve the best performance in the clinic. But we are excited about the potential of this immunoproteomics approach for Crohn's disease and will work to discover additional biomarkers."
-end-


Arizona State University

Related Immune System Articles:

Parkinson's and the immune system
Mutations in the Parkin gene are a common cause of hereditary forms of Parkinson's disease.
How an immune system regulator shifts the balance of immune cells
Researchers have provided new insight on the role of cyclic AMP (cAMP) in regulating the immune response.
Immune system upgrade
Theoretically, our immune system could detect and kill cancer cells.
Using the immune system as a defence against cancer
Research published today in the British Journal of Cancer has found that a naturally occurring molecule and a component of the immune system that can successfully target and kill cancer cells, can also encourage immunity against cancer resurgence.
First impressions go a long way in the immune system
An algorithm that predicts the immune response to a pathogen could lead to early diagnosis for such diseases as tuberculosis
Filming how our immune system kill bacteria
To kill bacteria in the blood, our immune system relies on nanomachines that can open deadly holes in their targets.
Putting the break on our immune system's response
Researchers have discovered how a tiny molecule known as miR-132 acts as a 'handbrake' on our immune system -- helping us fight infection.
Decoding the human immune system
For the first time ever, researchers are comprehensively sequencing the human immune system, which is billions of times larger than the human genome.
Masterswitch discovered in body's immune system
Scientists have discovered a critical part of the body's immune system with potentially major implications for the treatment of some of the most devastating diseases affecting humans.
How a fungus can cripple the immune system
An international research team led by Professor Oliver Werz of Friedrich Schiller University, Jena, has now discovered how the fungus knocks out the immune defenses, enabling a potentially fatal fungal infection to develop.
More Immune System News and Immune System Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Uncharted
There's so much we've yet to explore–from outer space to the deep ocean to our own brains. This hour, Manoush goes on a journey through those uncharted places, led by TED Science Curator David Biello.
Now Playing: Science for the People

#556 The Power of Friendship
It's 2020 and times are tough. Maybe some of us are learning about social distancing the hard way. Maybe we just are all a little anxious. No matter what, we could probably use a friend. But what is a friend, exactly? And why do we need them so much? This week host Bethany Brookshire speaks with Lydia Denworth, author of the new book "Friendship: The Evolution, Biology, and Extraordinary Power of Life's Fundamental Bond". This episode is hosted by Bethany Brookshire, science writer from Science News.
Now Playing: Radiolab

Dispatch 1: Numbers
In a recent Radiolab group huddle, with coronavirus unraveling around us, the team found themselves grappling with all the numbers connected to COVID-19. Our new found 6 foot bubbles of personal space. Three percent mortality rate (or 1, or 2, or 4). 7,000 cases (now, much much more). So in the wake of that meeting, we reflect on the onslaught of numbers - what they reveal, and what they hide.  Support Radiolab today at Radiolab.org/donate.